CA3185730A1 - Inhibitors of complement factor c3 and their medical uses - Google Patents
Inhibitors of complement factor c3 and their medical usesInfo
- Publication number
- CA3185730A1 CA3185730A1 CA3185730A CA3185730A CA3185730A1 CA 3185730 A1 CA3185730 A1 CA 3185730A1 CA 3185730 A CA3185730 A CA 3185730A CA 3185730 A CA3185730 A CA 3185730A CA 3185730 A1 CA3185730 A1 CA 3185730A1
- Authority
- CA
- Canada
- Prior art keywords
- peg3
- trp
- yglu
- sar
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20186297 | 2020-07-16 | ||
| EP20186297.6 | 2020-07-16 | ||
| PCT/EP2021/069798 WO2022013374A1 (en) | 2020-07-16 | 2021-07-15 | Inhibitors of complement factor c3 and their medical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3185730A1 true CA3185730A1 (en) | 2022-01-20 |
Family
ID=71661768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3185730A Pending CA3185730A1 (en) | 2020-07-16 | 2021-07-15 | Inhibitors of complement factor c3 and their medical uses |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230287051A1 (https=) |
| EP (1) | EP4182023A1 (https=) |
| JP (1) | JP2023538807A (https=) |
| KR (1) | KR20230039718A (https=) |
| CN (1) | CN116209671A (https=) |
| AU (1) | AU2021309548A1 (https=) |
| CA (1) | CA3185730A1 (https=) |
| CO (1) | CO2023001411A2 (https=) |
| IL (1) | IL299870A (https=) |
| MX (1) | MX2023000679A (https=) |
| WO (1) | WO2022013374A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020128624A (ru) | 2018-02-27 | 2022-03-28 | Зп Спв 3 К/С | Аналоги компстатина и их медицинское применение |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| CN120359233A (zh) * | 2022-11-24 | 2025-07-22 | 阿麦达斯制药美国有限责任公司 | 用于基于载体的疗法的坎普他汀类似物 |
| CN118812653A (zh) * | 2023-04-18 | 2024-10-22 | 成都奥达生物科技有限公司 | 一种长效坎普他汀化合物 |
| CN119219741A (zh) * | 2023-06-29 | 2024-12-31 | 刘晓蓉 | 新型补体抑制剂及其制备、应用和产品 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319897B1 (en) | 1996-03-13 | 2001-11-20 | John D. Lambris | Peptides which inhibit complement activation |
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| WO1999013899A1 (en) | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| PT1549333E (pt) | 2002-09-20 | 2012-01-03 | Univ Pennsylvania | Análogos de compstatina com actividade melhorada |
| EP2662089A3 (en) | 2005-10-08 | 2014-02-19 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| CN102977191B (zh) | 2005-11-28 | 2016-08-10 | 宾夕法尼亚州大学理事会 | 有效的c3补体抑制素类似物 |
| WO2008153963A1 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-c3 complex and use for rational drug design |
| CA2813049A1 (en) * | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| RU2606120C2 (ru) * | 2011-08-31 | 2017-01-10 | Хантсман Эдванст Матириалз (Свитзеленд) Гмбх | Способ пропитки реакторов с воздушным сердечником, подвергнутый пропитке реактор с воздушным сердечником и применение системы пропитки |
| CA2847862C (en) | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9512180B2 (en) | 2012-12-19 | 2016-12-06 | The Regents Of The University Of California | Compstatin analogs |
| US10213476B2 (en) * | 2014-03-17 | 2019-02-26 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved potency and pharmacokinetic properties |
| RU2020128624A (ru) * | 2018-02-27 | 2022-03-28 | Зп Спв 3 К/С | Аналоги компстатина и их медицинское применение |
| BR112022003760A2 (pt) * | 2019-08-27 | 2022-05-31 | Zp Spv 3 K/S | Análogos de compstatina e seus usos médicos |
-
2021
- 2021-07-15 IL IL299870A patent/IL299870A/en unknown
- 2021-07-15 WO PCT/EP2021/069798 patent/WO2022013374A1/en not_active Ceased
- 2021-07-15 JP JP2023502703A patent/JP2023538807A/ja active Pending
- 2021-07-15 US US18/016,490 patent/US20230287051A1/en active Pending
- 2021-07-15 MX MX2023000679A patent/MX2023000679A/es unknown
- 2021-07-15 EP EP21742144.5A patent/EP4182023A1/en active Pending
- 2021-07-15 KR KR1020237005557A patent/KR20230039718A/ko active Pending
- 2021-07-15 CN CN202180062742.5A patent/CN116209671A/zh active Pending
- 2021-07-15 CA CA3185730A patent/CA3185730A1/en active Pending
- 2021-07-15 AU AU2021309548A patent/AU2021309548A1/en active Pending
-
2023
- 2023-02-09 CO CONC2023/0001411A patent/CO2023001411A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4182023A1 (en) | 2023-05-24 |
| MX2023000679A (es) | 2023-04-18 |
| AU2021309548A1 (en) | 2023-02-23 |
| CO2023001411A2 (es) | 2023-02-16 |
| KR20230039718A (ko) | 2023-03-21 |
| IL299870A (en) | 2023-03-01 |
| WO2022013374A1 (en) | 2022-01-20 |
| US20230287051A1 (en) | 2023-09-14 |
| JP2023538807A (ja) | 2023-09-12 |
| CN116209671A (zh) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12600749B2 (en) | Compstatin analogues and their medical uses | |
| US20230287051A1 (en) | Inhibitors of complement factor c3 and their medical uses | |
| JP7711044B2 (ja) | コンプスタチン類似体及びその医学的使用 | |
| CN107206254B (zh) | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 | |
| EP3062823B1 (en) | Novel polypeptides | |
| US10213476B2 (en) | Compstatin analogs with improved potency and pharmacokinetic properties | |
| JP6583411B2 (ja) | 薬物複合体 | |
| HK40102364A (en) | Compstatin analogues and their medical uses | |
| EA051613B1 (ru) | Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине | |
| HK40102364B (en) | Compstatin analogues and their medical uses | |
| EA049126B1 (ru) | Аналоги компстатина и пути их медицинского применения | |
| HK40092906A (zh) | 补体因子c3的抑制剂及其医学用途 | |
| HK1227702B (en) | Novel polypeptides | |
| HK1227702A1 (en) | Novel polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20240910 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241203 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241210 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250507 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250507 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250627 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250715 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250715 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250715 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250922 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250922 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250922 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250922 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250923 |